Deals and Financings Alibaba will transfer Ali JK Nutritional Products into its online healthcare subsidiary, Alibaba Health, in a $1.4 billion transaction; JHL Biotech, a China-Taiwan biosimilar company, raised $106 million in convertible bonds before a $250 million Hong Kong IPO later this year; HitGen of Chengdu closed a $39 million Series B financing for its drug discovery operations including over 50 active drug discovery partnerships; Xynomic Pharma, a Delaware-Shanghai oncology drug development company, completed a Series B crossover financing, led by China healthcare investors; Zai Lab of Shanghai acquired global rights to a topical biologic treatment for inflammatory conditions developed by Crescendo Biologics of the UK ; Luye Pharma, a Yantai biopharma, will collaborate with Boston 's Elpis Biopharm to discover dual-target CAR-T drug candidates; vTv Therapeutics of the US out-licensed China and Pacific Rim rights for a clinical-stage inflammatory treatment to China 's Newsoara Biopharma; Shuwen Biotech of Deqing will partner with Hangzhou 's Bliss Biopharma to develop companion diagnostics for BlissBio’s oncology drug candidates; Link Health Group of Guangzhou in-licensed China rights to Lidoderm®, a lidocaine patch for post-herpetic neuralgia pain, from Teikoku Pharma; Trials and Approvals   Nanjing 's Legend Biotech, a GenScript Biotech subsidiary, reported FDA approval of a US Phase Ib/II trial for its CAR-T therapy, partnered with Janssen. Stock Symbols: (NYSE: BABA) (HK: 0241) (NSDQ: ZLAB) (HK: 2186) (NSDQ: VTVT) (HK: 1548)